オプションチェーンは、Sanofiの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Sanofiの市場センチメントを評価します。.

Sanofi (NASDAQ:SNY) 株価情報, オプションチェーン

Sanofi

Sanofi American Depositary Shares (Each repstg one-half of one ordinary share)

NYSE

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi SA

Synthetify

SUNNYLIFE GLOBAL INC by Sunnylife Global, Inc.

Sunnylife Global Inc

SANOFI ORD

Synergy CHC Corp

VITAL ENERGY INC (CDA) by Vital Energy, Inc.

Vital Energy Inc

SANY HEAVY EQUIP INTL HLD by Sany Heavy Equipment International Holdings Co.

Sany Heavy Equipment International Holdings Co Ltd

Just two weeks ago, Upstream Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of <a href="https://www.benzinga.com/pressreleases/24/10/g41344387/upstream-bio-announces-closing-of-293-million-upsized-initial-public-offering-including-full-exerc" target="_blank" rel="noreferrer noopener">approximately $293 million</a>.
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases with an initial focus on severe respiratory disorders.
<ul>
<li>Piper Sandler initiated coverage on Upstream Bio with an Overweight rating and a <a href="https://www.benzinga.com/quote/UPB/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $75</a>.</li>
<li>William Blair has also initiated coverage of Upstream Bio with an Outperform rating </li>
</ul>
Piper Sandler noted the company&#8217;s lead program, verekitug, has a differentiated mechanism of action that targets the TSLP receptor vs. ligand.
The TSLP ligand has been de-risked by AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) / Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Tezspire&#8217;s 2021 approval in severe asthma, the analyst says. It represents a rapidly growing biologic market opportunity of over $7.5 billion.
Piper analyst writes, &#8220;verekitug&#8217;s key advantage is its durability given its high potency, enabling Q12W dosing and potentially up to Q24W dosing, which is significantly lower compared to other biologics such as Tezspire (Q4W dosing) and Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) / Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (Q2W dosing).
William Blair also based its rating on the blockbuster potential of verekitug in large indications, including asthma and chronic obstructive pulmonary disease (COPD).
&#8220;The analyst writes that &#8220;Verekitug has the potential to deliver differentiated efficacy and longer dosing intervals than currently approved biologics for the treatment of asthma, most notably the TSLP antibody Tezspire, which targets the ligand.
William Blair writes that demonstrating clinical efficacy at least comparable to Tezspire, with dosing intervals of every three to six months, could position the therapy as a blockbuster, aligning with patient preferences for fewer doses.
However, early preclinical and clinical data for verekitug indicate a potential for even greater efficacy than Tezspire, which could exceed current baseline expectations.
Price Action: Upstream Bio stock is up 12.5% at $28.30 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41753290/ferrari-slows-down-q3-shipment-drop-hits-the-brakes-on-stock-growth" target="_blank" rel="noreferrer noopener">Ferrari Slows Down, Q3 Shipment Drop Hits the Brakes On Stock Growth</a></li>
</ul>

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

AMGN

REGN

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

On Thursday, Lexicon Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>)&nbsp;announced the outcome of the FDA&#8217;s Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company&#8217;s New Drug Application (NDA) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41667604/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquista-sotagliflozin-as-an-adjunct-to-i" rel="noreferrer noopener">for Zynquista (sotagliflozin)</a>.
The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).
The Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks, as having an estimated glomerular filtration rate (eGFR)&nbsp;&gt;45 to &lt;60 mL/min.1.73 m2&nbsp;or eGFR&nbsp;&gt;60 mL/min/1.73 m2&nbsp;and urine albumin-to-creatinine ratio (uACR)&nbsp;&gt;&nbsp;30mg/g.&nbsp;
As part of the discussion, certain committee members expressed support for sotagliflozin in alternative sub-populations of people with T1D and CKD, where they believed the benefits potentially outweigh the risks.
As previously reported, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of Dec. 20.
The FDA approved Sotagliflozin, branded as Inpefa, in May 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other <a target="_blank" href="https://www.benzinga.com/pressreleases/23/05/g32603118/lexicon-announces-fda-approval-of-inpefa-sotagliflozin-for-treatment-of-heart-failure" rel="noreferrer noopener">cardiovascular risk factors</a>.
In 2019, the FDA issued a complete response letter (CRL) regarding the NDA for sotagliflozin for type 1 diabetes. Despite FDA rejection, the European Medicines Agency <a target="_blank" href="https://www.lexpharma.com/media-center/news/zynquista-now-approved-in-the-european-union-for-treatment-of-adults-with-type-1-diabetes" rel="noreferrer noopener">approved</a> the drug in April 2019, covering TID patients who could not achieve adequate glycemic control despite optimal insulin therapy.
In 2021, at Lexicon's request, the FDA issued a public Notice of Opportunity for Hearing (NOOH) on whether there were grounds for denying such approval.
Lexicon and FDA subsequently agreed in late 2023 to hold the NOOH proceedings in abeyance to discuss a path forward for resubmission and potential approval of the NDA.
Lexicon Pharmaceuticals resubmitted its NDA for sotagliflozin in June. The company anticipated a six-month review and a potential <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39430661/lexicon-pharmaceuticals-resubmits-sotagliflozin-nda-for-type-1-diabetes" rel="noreferrer noopener">launch in early 2025</a>.
Also, in 2019, after four years of collaboration, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) <a target="_blank" href="https://www.lexpharma.com/media-center/news/lexicon-pharmaceuticals-announces-termination-of-alliance-and-settlement-with-sanofi" rel="noreferrer noopener">terminated</a> the sotagliflozin-related agreement and paid Lexicon Pharmaceuticals $260 million.
Two weeks ago, Viatris Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) obtained an exclusive license from Lexicon to commercialize sotagliflozin in all indications outside of the U.S. and Europe. Lexicon retains sole commercialization rights for sotagliflozin in all indications in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41368750/lexicon-announces-exclusive-licensing-agreement-with-viatris-for-sotagliflozin-in-all-markets-outs" rel="noreferrer noopener">the U.S. and Europe</a>.
Price Action: LXRX stock is down 38.46% at $1.22 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41661427/starbucks-faces-sales-slump-but-analysts-see-silver-lining-with-new-ceos-efficiency" target="_blank" rel="noreferrer noopener">Starbucks Faces Sales Slump But Analysts See Silver Lining With New CEO&#8217;s Efficiency Strategy</a></li>
</ul>
Photo: Shutterstock

LXRX

VTRS

FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes

On Thursday,&nbsp;Regeneron Pharmaceuticals&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)&nbsp;reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $11.69</a>.
The company reported sales of $3.72 billion, up 11%, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41647880/regeneron-reports-third-quarter-2024-financial-and-operating-results" rel="noreferrer noopener">consensus of $3.67 billion</a>.
&#8220;Regeneron&nbsp;had a strong third quarter marked by 11% revenue growth. We continued to deepen the impact of our commercialized medicines this quarter, with ongoing leadership for our retinal franchise, expanded global reach of Libtayo, and notable growth from Dupixent,&#8221; said&nbsp;Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of&nbsp;Regeneron.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41208078/regeneron-chief-flags-health-risks-with-popular-weight-loss-medications-like-ozempic-says-company" rel="noreferrer noopener">Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs</a>
&#8220;Our strong third quarter financial performance was highlighted by double-digit revenue growth and continued investment in our growing pipeline,&#8221; said Christopher Fenimore, Senior Vice President, Finance and Chief Financial Officer of Regeneron.
Third quarter 2024 U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;increased 3% versus third quarter 2023 to $1.54&nbsp;billion, including $392 million from Eylea HD.
A lower net selling price adversely impacted the net product sales of EYLEA in the third quarter of 2024.
Libtayo&nbsp;global net sales increased by 25% to $289 million.
Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) collaboration revenue increased from $1.06 billion to $1.26 billion.
The company said its obesity clinical program is now enrolling.
In its earnings <a target="_blank" href="https://investor.regeneron.com/static-files/4ac68b22-7abe-4d1f-a15a-2a9b739cc935" rel="noreferrer noopener">presentation</a>, Regeneron said Phase 2 study to investigate if addition of trevogrumab (anti-myostatin) to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide with and without garetosmab (antiactivin A) improves the quality of weight loss and/or improves maintenance of weight loss post semaglutide discontinuation.
Safety and tolerability data for high-dose trevogrumab in healthy volunteers showed no new safety signals.
The company is on track to complete enrollment by year-end 2024; results for both primary endpoints are expected in 2H25.
Price Action: REGN stock is down 10.7% at $824.28 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41656437/cignas-q3-profit-beats-street-on-strong-demand-for-pharmacy-benefit-managements-specialty-drugs-new" target="_blank" rel="noreferrer noopener">Cigna&#8217;s Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management&#8217;s Specialty Drugs, New Clients</a></li>
</ul>

Earnings

Large Cap

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

<a href="https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon" title="https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon">https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon</a>

NVAX

USDA Says H5N1 Bird Flu Detected In Swine For The First Time In U.S. In Oregon Backyard Farm; There Is No Concern About Safety Of The Nation's Pork Supply As A Result Of This Finding On HPAI Detections In Oregon Backyard Farm

USDA To Begin Bulk Milk Testing For Bird Flu Nationwide Following Pressure From Industry And Veterinary Groups; New Effort Aims To Curb Rapid Spread Among Dairy Herds

<a href="https://www.cdc.gov/bird-flu/spotlights/bird-flu-response-10-29-24.html#:~:text=Since%20April%202024%2C%20CDC%2C%20working,infected%20dairy%20cows12" title="https://www.cdc.gov/bird-flu/spotlights/bird-flu-response-10-29-24.html#:~:text=Since%20April%202024%2C%20CDC%2C%20working,infected%20dairy%20cows12">https://www.cdc.gov/bird-flu/spotlights/bird-flu-response-10-29-24.html#:~:text=Since%20April%202024%2C%20CDC%2C%20working,infected%20dairy%20cows12</a>.

Macro Notification

US CDC Reports 36 H5 Bird Flu Cases In U.S. Since April; Six Cases In Washington Poultry Workers Confirmed Last Week; No Person-To-Person Spread Detected; Public Risk Remains Low But Higher For Those Exposed To Infected Animals; 15 Cases Linked To Infected Poultry And 20 To Sick Dairy Cows

Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season.

Sanofi Says Beyfortus Will Be Broadly Available For Babies Born In Ontario, Quebec, Nunavut, Northwest Territories, And The Yukon This Fall

On Friday, Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), which will be presented at the Fall <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41540619/lillys-ebglyss-lebrikizumab-lbkz-demonstrated-meaningful-improvement-in-skin-clearance-and-itch-re" rel="noreferrer noopener">Clinical Dermatology Conference</a>.
The results show that Ebglyss improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) / Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab).
The study&#8217;s primary endpoint was measured by at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) score at 16 weeks, which evaluates the extent and severity of the skin disease.
Secondary endpoints at 16 and 24 weeks included Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with a reduction of at least two points from baseline and at least a four-point improvement in Pruritus NRS from baseline.
With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with dupilumab achieved EASI-75.
In addition, 46% of patients who were inadequate responders to dupilumab achieved EASI-75 response with Ebglyss at Week 16.
53% and 62% of ADapt patients who discontinued dupilumab and began treatment with Ebglyss also experienced itch relief (Pruritus NRS) with at least a four-point improvement from baseline at Week 16 and Week 24, respectively.
Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss.
52% treated with Ebglyss saw clear or almost clear face dermatitis at Week 24.
Among patients with moderate-to-severe hand dermatitis at baseline, the modified total lesion-symptom score, which measures the extent and severity of hand dermatitis, decreased by 75 percent at Week 24.
Less than 6% of patients treated with Ebglyss experienced an adverse event that led to treatment discontinuation.
Last month, the FDA approved Ebglyss, a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40884197/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss" rel="noreferrer noopener">topical prescription therapies</a>.
Ebglyss was also approved in the European Union in 2023 and Japan in January 2024, with additional markets expected later this year.
Price Action: LLY stock is up 0.32% at $894.15 at last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41551304/bkvs-integrated-operations-offer-value-analyst-highlights-unique-closed-loop-system" target="_blank" rel="noreferrer noopener">BKV&#8217;s Integrated Operations Offer Value, Analyst Highlights Unique &#8216;Closed-Loop&#8217; System And Growth Prospects</a></li>
</ul>

Equities

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

WIIM

Sanofi shares are trading higher after the company reported a year-over-year increase in Q3 adjusted EPS results and better-than-expected Q3 sales results.

On Friday,&nbsp;Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% <a target="_blank" href="https://www.benzinga.com/quote/SNY" rel="noreferrer noopener">in constant currency</a>.
The company <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-10-25-05-30-00-2969234" rel="noreferrer noopener">reported</a> third-quarter sales of 13.44 billion euros or $14.79 billion, beating the consensus of $13.97 billion.
Sales increased 12.3% year over year and 15.7% on constant currency, led by solid growth from Dupixent, Pharma launches, vaccines, and Opella.
The French drugmaker reported adjusted EPS of 2.86 euros or $1.57, up 12.2% (+17.6% on constant currency).
Sales of Dupixent, Sanofi&#8217;s blockbuster eczema drug, rose 23.8% to 3.48 billion euros.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease" rel="noreferrer noopener">FDA Approves Regeneron/Sanofi&#8217;s Blockbuster Dupixent For Smoker&#8217;s Lung Disease</a>
New pharma launches increased 67.1% to 727 million euros, led by Altuviiio (hemophilia&nbsp;drug), Nexviazyme (Pompe disease), and Rezurock (chronic graft-versus-host disease).
Vaccine sales were up 25.5% to 3.8 billion euros, boosted by the phasing of flu sales and by Beyfortus due to approved extra capacity.
Beyfortus (RSV) sales were 645 million euros, driven by early deliveries in the U.S. and rollout in several countries. In collaboration with AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), which is responsible for manufacturing, additional capacity enabled increased supply after a second external filling line was licensed.
Opella, Sanofi&#8217;s consumer healthcare business unit, generated sales of 1.3 billion euros, up 8%.
Guidance: Earlier this week, Sanofi updated its 2024 business EPS guidance to at least a low single-digit percentage at CER supported by the underlying strong business performance, reflecting the new scope of guidance <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41427490/sanofi-engages-in-exclusive-talks-with-us-private-equity-cd-r-for-its-consumer-health-business" rel="noreferrer noopener">excluding the Opella</a>.
Earlier the company expected business EPS to be stable <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39956385/sanofi-raises-2024-profit-outlook-on-strong-q2-earnings-blockbuster-drug-dupixent-sees-strong-dem" rel="noreferrer noopener">at constant currency</a>.
The company reaffirms that Dupixent will&nbsp;deliver around 13 billion euros in 2024 sales.
Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. 2024 vaccine sales are <a href="https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2024/2024-q3-2024-results/q3-2024-presentation-en.pdf" target="_blank" rel="noreferrer noopener">expected</a> to grow high single-digit compared to the earlier mid-single-digit range.
Sanofi forecasts Beyfortus sales for the fourth quarter to be similar to the third quarter.
Price Action: SNY stock is up 2.82% at $53.52 during the premarket session at the last check on Friday.
Image by HJBC via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41528255/googles-2b-investment-in-anthropic-under-scrutiny-uk-opens-competition-inquiry" target="_blank" rel="noreferrer noopener">Google&#8217;s $2B Investment in Anthropic Under Scrutiny, UK Opens Competition Inquiry</a></li>
</ul>

Guidance

Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast

2024 business EPS(1) guidance &bull; On October 21, 2024, the 2024 business EPS(1) guidance was upgraded to growth of at least a low single-digit percentage at CER(2) supported by the underlying strong business performance. This reflects the new scope of guidance excluding Opella detailed in the October 21, 2024 press release. Applying the average October 2024 exchange rates, the currency impact on 2024 business EPS(1) is estimated to be -5.5% to -6.5%

Sanofi Upgrades 2024 Business EPS Guidance To Low Single-Digit Growth At CER, Reflecting Strong Performance And Excluding Opella

Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) reported quarterly earnings of $1.57 per share. This is a 12.95 percent increase over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $14.796 billion which beat the analyst consensus estimate of $13.970 billion by 5.91 percent. This is a 13.62 percent increase over sales of $13.022 billion the same period last year.

Earnings Beats

Sanofi Q3 2024 Adj. EPS $1.57 Up From $1.39 YoY, Sales $14.796B Beat $13.970B Estimate

<a href="https://www.cdc.gov/bird-flu/spotlights/missouri-h5n1-serology-testing.html#:~:text=Conclusion%20of%20Missouri%20Investigation%3A,of%20five%20health%20care%20workers" title="https://www.cdc.gov/bird-flu/spotlights/missouri-h5n1-serology-testing.html#:~:text=Conclusion%20of%20Missouri%20Investigation%3A,of%20five%20health%20care%20workers">https://www.cdc.gov/bird-flu/spotlights/missouri-h5n1-serology-testing.html#:~:text=Conclusion%20of%20Missouri%20Investigation%3A,of%20five%20health%20care%20workers</a>.

CDC Issues Report On Missouri H5N1 Serology Testing; Confirms No Human-To-Human Transmission Of H5 Bird Flu Detected In US

Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) is gearing up to announce its quarterly earnings on Friday, 2024-10-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Sanofi will report an earnings per share (EPS) of $1.39.
Anticipation surrounds Sanofi's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.07, leading to a 1.32% drop in the share price the following trading session.
Here's a look at Sanofi's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.86</td>
<td>0.94</td>
<td>1.50</td>
<td>2.26</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.93</td>
<td>0.97</td>
<td>0.89</td>
<td>1.39</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>-19.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729778426_0.png" alt="eps graph" />
<h3>Market Performance of Sanofi's Stock</h3>
Shares of Sanofi were trading at $52.89 as of October 23. Over the last 52-week period, shares are up 23.12%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on Sanofi</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Sanofi.
Analysts have provided Sanofi with 1 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $60.0, suggesting a potential 13.44% upside.
<h3>Analyzing Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Pfizer, Zoetis and AstraZeneca, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>For Pfizer, analysts project an Outperform trajectory, with an average 1-year price target of $39.0, indicating a potential 26.26% downside.</li>
<li>Zoetis is maintaining an Buy status according to analysts, with an average 1-year price target of $212.5, indicating a potential 301.78% upside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for AstraZeneca, with an average 1-year price target of $95.0, indicating a potential 79.62% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Pfizer, Zoetis and AstraZeneca, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Neutral</td>
<td>8.69%</td>
<td>$8.93B</td>
<td>10.03%</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Outperform</td>
<td>2.13%</td>
<td>$9.98B</td>
<td>0.05%</td>
</tr>
<tr>
<td>Zoetis</td>
<td>Buy</td>
<td>8.30%</td>
<td>$1.69B</td>
<td>12.45%</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>Buy</td>
<td>13.33%</td>
<td>$10.76B</td>
<td>5.01%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Sanofi ranks in the middle for Consensus rating among its peers. It is at the bottom for Revenue Growth. Sanofi is at the top for Gross Profit. Sanofi is at the bottom for Return on Equity.
<h3>About Sanofi</h3>
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
<h3>Sanofi: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Sanofi displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 6.53%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Sanofi's net margin excels beyond industry benchmarks, reaching 9.78%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sanofi's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.53%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Sanofi's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.86%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Sanofi's debt-to-equity ratio is below the industry average. With a ratio of 0.33, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/SNY/earnings">To track all earnings releases for Sanofi visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sanofi's Earnings Outlook

Regeneron And Sanofi To Present Phase 3 LIBERTY-CUPID Study C Study Data Evaluating Dupixent; Says Dupixent Reduced Itch And Hive Activity From Baseline, 41% Of Patients Achieved Well-Controlled Disease Status

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and private equity Clayton Dubilier &amp; Rice (CD&amp;R) have finally entered into exclusive negotiations to potentially sell and purchase a 50% controlling stake in Opella, Sanofi&#8217;s consumer health unit.&nbsp;&nbsp;
The new step in Opella&#8217;s journey paves the way for <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-10-21-05-30-00-2965875" rel="noreferrer noopener">creating</a> a standalone player in consumer healthcare while supporting Sanofi&#8217;s strategy and increased focus on innovative medicines and vaccines.
Sanofi would remain a significant shareholder in Opella.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/10/41341084/sanofi-might-face-political-hurdles-in-16b-consumer-pharma-unit-sale-to-us-private-equity-cd-r" rel="noreferrer noopener">Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&amp;R</a>.
Bpifrance is expected to be a minority shareholder with a c.2% stake.
Headquartered in France, Opella employs over 11,000 people and operates in 100 countries. It has 13 manufacturing sites and four science and innovation development centers.
With a portfolio of brands, such as Allegra, Doliprane, and Dulcolax, Opella is the third-largest business worldwide in the over-the-counter and vitamins, minerals &amp; supplements market (OTC &amp; VMS), serving over half a billion consumers worldwide.
Opella operates in a fast-growing industry driven by sustainable long-term trends, such as an aging population, rising income levels, and greater health and well-being awareness.
Opella&#8217;s valuation is based on an enterprise value of c.€16 billion ($17.36 billion), corresponding to approximately 14 times the 2024 estimated EBITDA. CD&amp;R&#8217;s offer is binding and fully financed.
The proposed transaction is anticipated to close in the second quarter of 2025.
Under the new scope, excluding Opella, preliminary business EPS in 2023 was 7.25 euros. Sanofi expects its 2024 business EPS to grow by at least a low-single-digit percentage at CER.
For 2025, Sanofi continues to anticipate a strong rebound in business EPS at CER under the previous and the new scope.
Another French private equity, PAI Partners, reportedly raised its bid for Sanofi&#8217;s consumer health division by around 200 million euros ($217.12 million).
While CD&amp;R has emerged as the frontrunner, PAI and its partners, including Singapore&#8217;s GIC and the Abu Dhabi Investment Authority, argued that their French roots could better align with the&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/10/41341084/sanofi-might-face-political-hurdles-in-16b-consumer-pharma-unit-sale-to-us-private-equity-cd-r" rel="noreferrer noopener">country&#8217;s interests</a>.
However, PAI&#8217;s lower financial capacity compared to CD&amp;R, which raised a record 26 billion euros last year, was a disadvantage in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41407755/frances-pai-partners-ups-bid-for-sanofis-consumer-health-division-as-french-government-hints-poss" rel="noreferrer noopener">the bidding process</a>.
Price Action: SNY stock is down 0.87% at $54.45 during the premarket session at last check Monday.
Image by HJBC via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41409413/bofa-upgrades-tyra-biosciences-as-investors-focus-on-preclinical-data-amid-high-ben" target="_blank" rel="noreferrer noopener">BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson &amp; Johnson&#8217;s Drug</a>.</li>
</ul>

Asset Sales

Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business

Guidance
The original 2024 business EPS&nbsp;guidance&nbsp;issued on February 1, 2024, and upgraded on July 25, 2024, anticipated Opella as a fully consolidated segment in Sanofi for 2024. Under the previous scope of&nbsp;guidance&nbsp;including Opella, Sanofi would have upgraded its 2024 business EPS&nbsp;guidance&nbsp;to between stable to a low single-digit percentage growth at CER3, from previously stable at CER. This upgrade is substantiated by an expected strong business performance in the&nbsp;third quarter&nbsp;that will be detailed as part of&nbsp;Q3&nbsp;2024 results.
Under the new scope excluding Opella, preliminary business EPS in 2023 was &euro;7.25. Sanofi expects its 2024 business EPS to grow by at least a low-single digit percentage at CER.
For 2025, Sanofi continues to anticipate a strong rebound in business EPS at CER under both the previous and the new scope.

Sanofi Eyes Low Single-Digit EPS Growth For 2024 After Opella Stake Transfer, Forecasts Strong Rebound In 2025

Sanofi and CD&amp;R partner to fuel Opella&#39;s ambitions in consumer healthcare
<ul>
<li>Sanofi and CD&amp;R enter exclusive negotiations to transfer a&nbsp;50%&nbsp;controlling stake in Opella with Sanofi to remain a significant shareholder</li>
<li>With 11,000 talented and passionate people bringing iconic brands to life, Opella poised to ignite new bold development journey</li>
<li>Sanofi to become a focused science-driven biopharma delivering innovative medicines and vaccines to patients</li>
<li>Sanofi 2024 business EPS&nbsp;guidance&nbsp;upgraded today</li>
</ul>

Sanofi And CD&R Enter Exclusive Talks To Shape Opella's Global Healthcare Journey, Sanofi To Remain A Significant Shareholder

<a href="https://www.bloomberg.com/news/articles/2024-10-18/sanofi-set-to-sign-consumer-health-deal-with-cd-r-this-weekend?utm_source=google&amp;utm_medium=bd&amp;cmpId=google" title="https://www.bloomberg.com/news/articles/2024-10-18/sanofi-set-to-sign-consumer-health-deal-with-cd-r-this-weekend?utm_source=google&amp;utm_medium=bd&amp;cmpId=google">https://www.bloomberg.com/news/articles/2024-10-18/sanofi-set-to-sign-consumer-health-deal-with-cd-r-this-weekend?utm_source=google&amp;utm_medium=bd&amp;cmpId=google</a>

'Sanofi Set to Sign Consumer Health Deal With CD&R This Weekend' - Bloomberg

On Friday,&nbsp;Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) announced that the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion <a target="_blank" href="https://www.benzinga.com/general/biotech/22/12/29990021/novartis-kisqali-prolongs-progression-free-survival-benefit-in-metastatic-breast-cancer-versus-ch" rel="noreferrer noopener">for Kisqali (ribociclib)</a>.
The CHMP recommended approval granting marketing authorization for Kisqali (ribociclib) for the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC), at high risk of disease recurrence, <a target="_blank" href="https://www.benzinga.com//node/41399115" rel="noreferrer noopener">including those with node-negative disease.</a>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40738489/goldman-sachs-shifts-stance-on-novartis-cites-lack-of-near-term-catalysts" rel="noreferrer noopener">Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts</a>.
The CHMP decision is based on data from the Phase 3 NATALEE trial.
In the trial, Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.1% in patients with stage II and III HR+/HER2- EBC.
The data also demonstrated a consistent, clinically meaningful invasive disease-free survival (iDFS) benefit across key pre-specified subgroups.
Data from the pivotal trial also showed that the safety profile of Kisqali at the 400mg dose was well-tolerated, with generally low-grade symptomatic adverse events.
The European Commission (EC) will decide in approximately two months.
Last month, Novartis released new data from the ALITHIOS open-label extension study.
Data show first-line Kesimpta&nbsp;(ofatumumab) treatment for up to six years led to less disability and disease progression in recently diagnosed (≤3 years) and treatment-naïve (RDTN) people with relapsing multiple sclerosis (RMS), compared to those who switched from&nbsp;Sanofi SA&#8216;s <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40923550/novartis-multiple-sclerosis-drug-data-shows-most-patients-remain-with-no-disability-progression-f" rel="noreferrer noopener">Aubagio (teriflunomide)</a>.
Price Action: NVS stock is up 0.35% at $116.92 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41404275/whats-going-on-with-treehouse-foods-stock-today" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With TreeHouse Foods Stock Today?</a></li>
</ul>

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer

Sanofi ($SNY) gained in pre-market trading after the company reported robust Q3 results. The French pharmaceutical and healthcare company reported ...

SNY Earnings: Sanofi Shines with Strong Q3 Earnings, Surpassing Expectations

Lilly's Ebglyss shown to be effective in former Dupixent users

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: A U.S. judge has blocked the proposed ...

Judge blocks Tapestry-Capri deal, Centene reports Q3 beat: Morning Buzz

Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine and p...

Sanofi Reports Strong Q3 Growth and Raises EPS Guidance

Sanofi (SNY) Q3 2024 Earnings Call Transcript

In a report released today, Elmar Kraus from DZ BANK AG maintained a Hold rating on Sanofi (SNYNF – Research Report). The company's shares closed l...

DZ BANK AG Sticks to Its Hold Rating for Sanofi (SNYNF)

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Sanofi (SNYNF – Research Report), with a price target...

Sanofi (SNYNF) Receives a Sell from Deutsche Bank

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €112.00. David Risin...

Sanofi Positioned for Growth: Analyst David Risinger Recommends Buy Amid Strong Earnings Outlook

Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this f...

Sanofi says Beyfortus to be broadly available in more Canadian territories soon

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

AAPL

BYON

CPRI

DBRG

DECK

JOBY

MSFT

NYCB

PIPR

RHHBF

RHHBY

RHHVF

SNYNF

TMHC

TMUS

TSLA

TYRA

Redington 2_29

BDRX

PowerShares Dynamic Financial Sector Portfolio

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Financing

Press Releases

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

Sanofi ships U.S. influenza vaccines for the 2024/25 season

Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season

Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza

Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA

Opinion

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

Beyfortus® immunization to protect infants from RSV has begun

ANVS

GTHX

HALO

ONCY

TSX:ONC

VIGL

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Sanofi

Sanofi (SNY) オプション

Sanofi (NASDAQ:SNY) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル